Treatment for Panic Disorder
Start with an SSRI (selective serotonin reuptake inhibitor) or SNRI (serotonin-norepinephrine reuptake inhibitor) combined with cognitive behavioral therapy (CBT) for optimal outcomes in panic disorder. 1
First-Line Treatment Approach
The evidence strongly supports a dual-modality strategy:
Pharmacotherapy
SSRIs are the gold standard first-line medication 1, 2, 3, 4, 5
SNRIs are equally effective as first-line agents 1, 5
- Venlafaxine at 112.5-187.5 mg/day demonstrated significant reductions in panic symptoms 6
Psychotherapy
Combined Treatment Superiority
The combination of pharmacotherapy and CBT produces better outcomes than either modality alone 6, 1, 3, 7. This is the most successful treatment strategy for panic disorder. When patients fail to respond adequately to 12 sessions of CBT alone, adding an SSRI produces significantly greater symptom reduction 6.
Alternative and Augmentation Strategies
Second-Line Medications
Tricyclic antidepressants (TCAs) are equally effective but less well tolerated than SSRIs 1, 3, 5
- Imipramine is the most studied TCA
- Side effect profile limits their use as first-line agents
MAOIs can be efficacious but have significant dietary restrictions and drug interactions that preclude first-line use 1, 4
Benzodiazepines: Use With Caution
Benzodiazepines should NOT be first-line treatment despite demonstrating short-term efficacy 1. They are reserved for:
- Short-term use only (first few weeks while waiting for SSRI/SNRI onset) 4, 5
- Treatment-resistant cases without history of substance dependence 3, 5
- Clonazepam at 1.5-3 mg/day can be used as augmentation 6
Critical caveat: The 2025 Brazilian guidelines explicitly state benzodiazepines are not recommended as first-line due to dependency concerns and long-term risks 1.
Treatment-Resistant Cases
When patients fail initial SSRI/SNRI treatment:
Increase the SSRI dose before switching (though one study showed no difference between continuing current dose vs. increasing) 6
Add CBT if not already implemented - 12 weekly sessions of CBT augmentation showed equivalent efficacy to clonazepam augmentation in SSRI non-responders 6
Consider augmentation strategies:
Switch to alternative antidepressant class if no response after adequate trial
Treatment Duration
Continue medications for 6-12 months after remission 5. Relapse is frequent with premature discontinuation, as panic disorder is often chronic 7. Long-term treatment is necessary due to the chronicity of the illness.
What NOT to Do
- Do not use eye movement desensitization and reprocessing (EMDR) for panic disorder - not recommended by guidelines 8
- Do not use exposure therapy alone without CBT framework - not recommended 8
- Do not use benzodiazepines as monotherapy for long-term management 1
- Do not stop treatment prematurely - minimum 6 months continuation after remission 5
Practical Implementation Algorithm
Initiate SSRI (e.g., sertraline 25-50 mg, titrate to 150-200 mg) OR SNRI (e.g., venlafaxine 75 mg, titrate to 150-225 mg)
Simultaneously refer for CBT with interoceptive exposure component (12 weekly sessions)
Consider short-term benzodiazepine (2-4 weeks) only if severe acute symptoms while awaiting antidepressant onset
Assess response at 6-8 weeks:
- If inadequate response: increase dose or add CBT if not already implemented
- If partial response: continue and reassess at 12 weeks
- If no response: switch antidepressant class or add augmentation
Continue treatment 6-12 months after achieving remission before considering taper
This evidence-based approach prioritizes both immediate symptom control and long-term remission while minimizing risks of dependency and maximizing quality of life outcomes.